Tag: pharyngitis treatment market share

Uncover key drivers, emerging technologies, and competitive movements shaping the pharyngitis treatment market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Pharyngitis Treatment Market expected to reach by 2030?

The pharyngitis treatment market has experienced robust expansion in recent times. This market is projected to expand from $2.37 billion in 2025 to reach $2.5 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 5.6%. Historically, this growth was driven by several factors, including an increased occurrence of upper respiratory infections, the extensive application of antibiotics in primary care, the accessibility of broad-spectrum antibiotics, the development of hospital treatment protocols, and the proliferation of outpatient treatment environments.

The pharyngitis treatment market size is projected to experience substantial growth in the upcoming years, with forecasts indicating it will reach $3.23 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.7%. This projected growth is driven by a heightened focus on precision infection management, an increasing demand for resistance-aware therapies, the broader availability of digital diagnosis platforms, escalating investments in developing new antibiotics, and the wider acceptance of home-based treatment models. Significant trends expected during this forecast period include the increasing creation of targeted antibiotic therapies, a rise in the use of rapid diagnostic support tools, the growing application of combination drug regimens, the expansion of telemedicine-linked treatment models, and a stronger emphasis on antimicrobial stewardship.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12937&type=smp

What Drivers Are Driving Adoption Within The Pharyngitis Treatment Market?

An increasing occurrence of influenza is anticipated to propel the growth of the pharyngitis treatment market going forward. Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. Pharyngitis treatment is primarily utilized to address influenza and proves beneficial for the flu by alleviating its symptoms, such as inflammation or irritation, with a focus on relieving allergies and preventing complications like pneumonia and bronchitis. For instance, in July 2023, according to the European Centre for Disease Prevention and Control (ECDC), a Sweden-based government agency, the percentage of positive influenza specimens in the 2022/2023 influenza season in the EU/EEA reached 28% from week 5 to week 12 of 2023. Therefore, this escalating incidence is a key driver for the growth of the pharyngitis treatment market.

What Segments Are Included Within The Pharyngitis Treatment Market?

The pharyngitis treatment market covered in this report is segmented –

1) By Drug Class: Beta Lactams, Macrolides, Cephalosporins, Fluoroquinolones, Tetracycline, Other Drug Classes

2) By Source Of Infection: Viral, Bacterial

3) By Modes Of Delivery: Oral, Intravenous, Intramuscular, Other Modes Of Delivery

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Beta Lactams: Penicillins, Amoxicillin, Ampicillin

2) By Macrolides: Erythromycin, Azithromycin, Clarithromycin

3) By Cephalosporins: Cefuroxime, Ceftriaxone, Cefdinir

4) By Fluoroquinolones: Ciprofloxacin, Levofloxacin, Moxifloxacin

5) By Tetracycline: Doxycycline, Minocycline, Tetracycline

6) By Other Drug Classes: Clindamycin, Sulfonamides, Carbapenems

What Long-Term Trends Are Expected To Shape The Future Of The Pharyngitis Treatment Market?

Leading companies operating in the pharyngitis treatment market are concentrating on developing innovative products such as oral monotherapy to enhance patient compliance and provide effective, convenient treatment options. Oral monotherapy refers to the use of a single drug or medication administered orally (by mouth) for treating a specific condition or disease. It involves the administration of just one therapeutic agent, as opposed to a combination of multiple treatments, to achieve the desired therapeutic effect. For instance, in December 2023, Novartis AG, a Switzerland-based pharmaceutical corporation, received FDA approval for Fabhalta (iptacopan), establishing it as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH). This milestone, achieved on [date], represents a significant advancement by offering a new treatment option that enhances hemoglobin levels, eliminating the need for blood transfusions.

Who Are The Major Companies Operating In The Pharyngitis Treatment Market?

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Aurobindo Pharma Limited, Sandoz Group AG, Alkem Laboratories Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Pharyngitis Treatment Market?

North America was the largest region in the pharyngitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharyngitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pharyngitis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12937&type=smp

Browse Through More Reports Similar to the Global Pharyngitis Treatment Market 2026, By The Business Research Company

Tracheitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/tracheitis-treatment-global-market-report

Sinusitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/sinusitis-treatment-global-market-report

Strep Throat Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/strep-throat-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pharyngitis treatment market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Pharyngitis Treatment Market expected to reach by 2030?

The pharyngitis treatment market has experienced robust expansion in recent times. This market is projected to expand from $2.37 billion in 2025 to reach $2.5 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 5.6%. Historically, this growth was driven by several factors, including an increased occurrence of upper respiratory infections, the extensive application of antibiotics in primary care, the accessibility of broad-spectrum antibiotics, the development of hospital treatment protocols, and the proliferation of outpatient treatment environments.

The pharyngitis treatment market size is projected to experience substantial growth in the upcoming years, with forecasts indicating it will reach $3.23 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.7%. This projected growth is driven by a heightened focus on precision infection management, an increasing demand for resistance-aware therapies, the broader availability of digital diagnosis platforms, escalating investments in developing new antibiotics, and the wider acceptance of home-based treatment models. Significant trends expected during this forecast period include the increasing creation of targeted antibiotic therapies, a rise in the use of rapid diagnostic support tools, the growing application of combination drug regimens, the expansion of telemedicine-linked treatment models, and a stronger emphasis on antimicrobial stewardship.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12937&type=smp

What Drivers Are Driving Adoption Within The Pharyngitis Treatment Market?

An increasing occurrence of influenza is anticipated to propel the growth of the pharyngitis treatment market going forward. Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. Pharyngitis treatment is primarily utilized to address influenza and proves beneficial for the flu by alleviating its symptoms, such as inflammation or irritation, with a focus on relieving allergies and preventing complications like pneumonia and bronchitis. For instance, in July 2023, according to the European Centre for Disease Prevention and Control (ECDC), a Sweden-based government agency, the percentage of positive influenza specimens in the 2022/2023 influenza season in the EU/EEA reached 28% from week 5 to week 12 of 2023. Therefore, this escalating incidence is a key driver for the growth of the pharyngitis treatment market.

What Segments Are Included Within The Pharyngitis Treatment Market?

The pharyngitis treatment market covered in this report is segmented –

1) By Drug Class: Beta Lactams, Macrolides, Cephalosporins, Fluoroquinolones, Tetracycline, Other Drug Classes

2) By Source Of Infection: Viral, Bacterial

3) By Modes Of Delivery: Oral, Intravenous, Intramuscular, Other Modes Of Delivery

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Beta Lactams: Penicillins, Amoxicillin, Ampicillin

2) By Macrolides: Erythromycin, Azithromycin, Clarithromycin

3) By Cephalosporins: Cefuroxime, Ceftriaxone, Cefdinir

4) By Fluoroquinolones: Ciprofloxacin, Levofloxacin, Moxifloxacin

5) By Tetracycline: Doxycycline, Minocycline, Tetracycline

6) By Other Drug Classes: Clindamycin, Sulfonamides, Carbapenems

What Long-Term Trends Are Expected To Shape The Future Of The Pharyngitis Treatment Market?

Leading companies operating in the pharyngitis treatment market are concentrating on developing innovative products such as oral monotherapy to enhance patient compliance and provide effective, convenient treatment options. Oral monotherapy refers to the use of a single drug or medication administered orally (by mouth) for treating a specific condition or disease. It involves the administration of just one therapeutic agent, as opposed to a combination of multiple treatments, to achieve the desired therapeutic effect. For instance, in December 2023, Novartis AG, a Switzerland-based pharmaceutical corporation, received FDA approval for Fabhalta (iptacopan), establishing it as the first oral monotherapy for adults with paroxysmal nocturnal hemoglobinuria (PNH). This milestone, achieved on [date], represents a significant advancement by offering a new treatment option that enhances hemoglobin levels, eliminating the need for blood transfusions.

Who Are The Major Companies Operating In The Pharyngitis Treatment Market?

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Aurobindo Pharma Limited, Sandoz Group AG, Alkem Laboratories Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Pharyngitis Treatment Market?

North America was the largest region in the pharyngitis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharyngitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pharyngitis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12937&type=smp

Browse Through More Reports Similar to the Global Pharyngitis Treatment Market 2026, By The Business Research Company

Tracheitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/tracheitis-treatment-global-market-report

Sinusitis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/sinusitis-treatment-global-market-report

Strep Throat Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/strep-throat-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Will The Pharyngitis Treatment Market Valuation Change Between Now And 2029?

In recent times, there has been a consistent expansion in the pharyngitis treatment market size. It is projected to escalate from $2.27 billion in 2024 to $2.37 billion in 2025, with a compound annual growth rate (CAGR) of 4.2%. The growth observed in the historic period is due to the high occurrence and increasing incidents of flu, mounting prevalence of pharyngitis, the increase in awareness about pharyngitis, better access to healthcare facilities, and increasing disposable incomes.

The market for pharyngitis treatment is forecasted to experience robust expansion in the upcoming years, growing to $3 billion by 2029 with an annual compound growth rate (CAGR) of 6.1%. This growth trajectory in the projected period is due to factors such as the uptake of rapid point-of-care tests, the demand for personalized medical treatments, increasing instances of antibiotic resistance, and the growing emphasis on hand hygiene. Key trends to watch during this forecast period include the progression in pharyngitis treatment research, digital health technology improvements, and the integration of telehealth.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12937&type=smp

What Underlying Factors Are Supporting The Pharyngitis Treatment Market Growth?

An increment in cases of strep throat transmission is predicted to spur the progression of the pharyngitis treatment market. Being a contagious bacterial infection, strep throat predominantly influences the throat and tonsils. Swift and efficient treatment of this infection with antibiotics can alleviate symptoms, ward off potential complications, and curtail the likelihood of transmitting the infection to others. For example, in June 2022, data from the Centers for Disease Control and Prevention, a government agency in the United States, revealed that an estimated 14,000 to 25,000 cases of invasive group A strep disease are reported annually in the US. Moreover, strep diseases result in 5.2 million outpatient visits and necessitate 2.8 million antibiotic prescriptions every year. Hence, the escalating transmission of strep throat fuels the growth of the pharyngitis treatment market.

Which Sub-Segments Are Driving Growth Within The Pharyngitis Treatment Market?

The pharyngitis treatmentmarket covered in this report is segmented –

1) By Drug Class: Beta Lactams; Macrolides; Cephalosporins; Fluoroquinolones; Tetracycline; Other Drug Classes

2) By Source of Infection: Viral; Bacterial

3) By Modes Of Delivery: Oral; Intravenous; Intramuscular; Other Modes Of Delivery

4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users

Subsegments:

1) By Beta Lactams: Penicillins; Amoxicillin; Ampicillin

2) By Macrolides: Erythromycin; Azithromycin; Clarithromycin

3) By Cephalosporins: Cefuroxime; Ceftriaxone; Cefdinir

4) By Fluoroquinolones: Ciprofloxacin; Levofloxacin; Moxifloxacin

5) By Tetracycline: Doxycycline; Minocycline; Tetracycline

6) By Other Drug Classes: Clindamycin; Sulfonamides; Carbapenems

What Current And Upcoming Trends Are Shaping The Pharyngitis Treatment Market?

Leading corporations engaged in the pharyngitis treatment market are channeling their focus towards the evolution of innovative solutions such as oral monotherapy. This approach aims to boost patient adherence by providing effective and convenient therapeutic options. Oral monotherapy signifies the oral administration of a singular medicinal drug to battle a particular disease or condition. This therapy style employs only one therapeutic agent instead of a combination of them to deliver the sought-after curative effect. For example, in December 2023, Novartis AG, a Switzerland-based pharmaceutical corporation secured FDA approval for Fabhalta (iptacopan), establishing it as the first-ever oral monotherapy for adults suffering from paroxysmal nocturnal hemoglobinuria (PNH). This achievement hit its mark on [date], symbolizing a substantial breakthrough by offering a new treatment that improves hemoglobin levels and eradicates the necessity for blood transfusions.

Which Companies Hold A Competitive Edge In The 721 Market?

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

Which Region Dominates The Pharyngitis Treatment Market Today?

North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12937&type=smp

Browse Through More Reports Similar to the Global Pharyngitis Treatment Market 2025, By The Business Research Company

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Non Steroidal Anti Inflammatory Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Cystic Fibrosis Cf Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Pharyngitis Treatment Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The pharyngitis treatment market has experienced steady growth in its size during recent years. Projections indicate a rise from $2.27 billion in 2024 to $2.37 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.2%. Historically, this expansion has been driven by factors such as the significant prevalence and increasing occurrence of influenza, the rising incidence of pharyngitis, heightened public understanding of pharyngitis, better availability of healthcare services, and an increase in disposable incomes.

The pharyngitis treatment market is anticipated to experience robust expansion over the coming years. It is projected to reach $3 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.1%. This growth during the forecast period is attributable to factors such as the increasing adoption of rapid point-of-care tests, the growing demand for personalized medicine, the widespread prevalence of antibiotic resistance, and the increasing significance of hand hygiene. Key trends anticipated in the forecast period encompass advancements in the research and development of pharyngitis therapies, the proliferation of digital health technologies, and enhanced telehealth integration.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12937&type=smp

Which Industry Drivers Are Expected To Accelerate The Pharyngitis Treatment Market From 2025 To 2029?

The increased incidence of strep throat is expected to propel the growth of the pharyngitis treatment market going forward. Strep throat is a contagious bacterial infection primarily affecting the throat and tonsils. Prompt and effective antibiotic treatment for strep throat helps to alleviate symptoms, prevent complications, and reduce the risk of spreading the infection to others. For instance, in June 2022, data from the Centers for Disease Control and Prevention, a US-based government agency, showed that approximately 14,000 to 25,000 cases of invasive group A strep disease occur every year in the United States. Additionally, strep diseases account for 5.2 million outpatient visits and 2.8 million antibiotic prescriptions annually. Therefore, the rising transmission of strep throat drives the pharyngitis treatment market.

What Are The Key Segments In The Pharyngitis Treatment Market?

The pharyngitis treatmentmarket covered in this report is segmented –

1) By Drug Class: Beta Lactams; Macrolides; Cephalosporins; Fluoroquinolones; Tetracycline; Other Drug Classes

2) By Source of Infection: Viral; Bacterial

3) By Modes Of Delivery: Oral; Intravenous; Intramuscular; Other Modes Of Delivery

4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users

Subsegments:

1) By Beta Lactams: Penicillins; Amoxicillin; Ampicillin

2) By Macrolides: Erythromycin; Azithromycin; Clarithromycin

3) By Cephalosporins: Cefuroxime; Ceftriaxone; Cefdinir

4) By Fluoroquinolones: Ciprofloxacin; Levofloxacin; Moxifloxacin

5) By Tetracycline: Doxycycline; Minocycline; Tetracycline

6) By Other Drug Classes: Clindamycin; Sulfonamides; Carbapenems

Which Competitive Trends Are Defining The Pharyngitis Treatment Market Structure?

Key companies active in the pharyngitis treatment market are prioritizing the creation of advanced products, such as oral monotherapy, to boost patient adherence and deliver efficient, convenient therapeutic choices. Oral monotherapy denotes the application of a singular drug or medicine taken orally to address a specific ailment or condition. This approach involves administering only one therapeutic agent, in contrast to combining multiple treatments, to achieve the desired effect. For example, in December 2023, Novartis AG, a pharmaceutical company based in Switzerland, obtained FDA approval for Fabhalta (iptacopan), positioning it as the inaugural oral monotherapy for adults diagnosed with paroxysmal nocturnal hemoglobinuria (PNH). This landmark, achieved on [date], signifies a considerable leap forward by providing a new treatment alternative that elevates hemoglobin levels, thus eradicating the necessity for blood transfusions.

Who Are The Core Companies Influencing The Pharyngitis Treatment Market Landscape?

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

How Do Regional Market Performances Compare Within The Pharyngitis Treatment Industry?

North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Pharyngitis Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12937&type=smp

Browse Through More Reports Similar to the Global Pharyngitis Treatment Market 2025, By The Business Research Company

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Non Steroidal Anti Inflammatory Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Cystic Fibrosis Cf Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Pharyngitis Treatment Market Size Changed, over the years?

In recent times, the market size for pharyngitis treatment has expanded continuously. It is projected to escalate from $2.27 billion in 2024 to approximately $2.37 billion in 2025, advancing at a compound annual growth rate (CAGR) of 4.5%. The expansion during the historic period is primarily due to a high number of recorded flu cases, an increased incidence of pharyngitis, raising awareness regarding pharyngitis, improved accessibility to healthcare facilities, and soaring personal disposable income.

How Much Will the Pharyngitis Treatment Market Be Worth in 2029?

The market size for pharyngitis treatment is set for robust expansion in the coming years, reaching a projected value of $2.99 billion by 2029, experiencing a compound annual growth rate of 6.0%. This predicted growth for the forecast period is due to several factors including the growing implementation of rapid point-of-care tests, increased demand for personalized medicine, the prevalence of antibiotic resistance, and a heightened focus on hand hygiene. Key trends projected for this forecast period encompass further advancements in research and development of pharyngitis therapies and the integration of digital health technologies and telehealth.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12937&type=smp

Which is the Largest Company in the Pharyngitis Treatment Market?

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

What Are the Main Market Drivers in the Pharyngitis Treatment Industry?

With a surge in the transmission of strep throat, the pharyngitis treatment market is set to witness an upward trajectory in its growth. Strep throat is an infectious bacterial disease primarily concentrated in the tonsils and throat. Timely and effective adherence to antibiotic treatments can help lessen the symptoms, reduce the chances of complications, and diminish the possibility of passing the infection onto others. As per data released by the Centers for Disease Control and Prevention, a government agency based in the United States, annually, there are reported around 14,000 to 25,000 incidents of invasive Group A strep disease within the country. Furthermore, strep diseases result in about 5.2 million outpatient visits along with around 2.8 million antibiotic prescriptions every year. This surge in strep throat transmission is instrumental in propelling the pharyngitis treatment market. Pharyngitis Treatment Market Driver: The pharyngitis treatment market is set to grow due to an escalation in cases of influenza. Influenza, also known as the flu, is an infectious disease affecting the respiratory system and is caused by influenza viruses. Treatments for pharyngitis are largely administered to treat influenza, and these are instrumental in soothing symptoms, which primarily include inflammation or irritation, besides focusing on relieving allergies and preventing possible complications such as bronchitis and pneumonia. As per a report by the European Centre for Disease Prevention and Control (ECDC), a government agency based in Sweden, during the 2022/2023 influenza season within the EU/EEA, the weekly percentage of positive influenza specimens reached a high of 42% in the 51st week of 2022. Thereafter, the positivity rate stayed around 28% from the 5th to the 12th week of 2023. The increasing incidence of influenza is therefore boosting the growth of the pharyngitis treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12937&type=smp

How Is the Pharyngitis Treatment Market Segments Structured?

The pharyngitis treatment market covered in this report is segmented –

1) By Drug Class: Beta Lactams, Macrolides, Cephalosporins, Fluoroquinolones, Tetracycline, Other Drug Classes

2) By Source of Infection: Viral, Bacterial

3) By Modes Of Delivery: Oral, Intravenous, Intramuscular, Other Modes Of Delivery

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Beta Lactams: Penicillins, Amoxicillin, Ampicillin

2) By Macrolides: Erythromycin, Azithromycin, Clarithromycin

3) By Cephalosporins: Cefuroxime, Ceftriaxone, Cefdinir

4) By Fluoroquinolones: Ciprofloxacin, Levofloxacin, Moxifloxacin

5) By Tetracycline: Doxycycline, Minocycline, Tetracycline

6) By Other Drug Classes: Clindamycin, Sulfonamides, Carbapenems

What Strategic Trends Are Transforming the Pharyngitis Treatment Market?

Leading enterprises within the pharyngitis treatment industry are concentrating their efforts on pioneering novel product solutions like oral monotherapy for improved patient adherence and to offer efficacious, accessible treatment options. Oral monotherapy involves usage of a singular pharmaceutical or medication orally ingested for the management of a particular disease or condition. The method solely includes one therapeutic agent instead of multiple treatments to accomplish the required therapeutic effect. For example, in December 2023, Swiss pharmaceutical firm Novartis AG received FDA endorsement for Fabhalta (iptacopan), marking it as the inaugural oral monotherapy for grown-up patients with paroxysmal nocturnal hemoglobinuria (PNH). This achievement, realized on [date], embodies a substantial progress by introducing a fresh treatment alternative that boosts hemoglobin quantities, thereby eliminating the necessity for blood transfusions.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

Which Global Regions Offer the Highest Growth in the Pharyngitis Treatment Market?

North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12937

This Report Delivers Insight On:

1. How big is the pharyngitis treatment market, and how is it changing globally?

2. Who are the major companies in the pharyngitis treatment market, and how are they performing?

3. What are the key opportunities and risks in the pharyngitis treatment market right now?

4. Which products or customer segments are growing the most in the pharyngitis treatment market?

5. What factors are helping or slowing down the growth of the pharyngitis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Pharyngitis Treatment Market?

The expected increase in strep throat transmission is predicted to foster the expansion of the pharyngitis treatment market. Strep throat, a communicable bacterial infection, has its primary effect on the throat and tonsils. Swift and efficient treatment of this condition with antibiotics can relieve symptoms, thwart complications, and decrease the risk of infection transmission. For example, in June 2022, as per the US-based government agency – the Centers for Disease Control and Prevention, roughly 14,000 to 25,000 cases of invasive group A strep disease are diagnosed in the United States every year. In addition, strep diseases result in 5.2 million outpatient visits and 2.8 million antibiotic prescriptions every year. The escalating transmission of strep throat, therefore, influences the pharyngitis treatment market. An uptick in influenza cases is anticipated to spur the growth of the pharyngitis treatment market in the future. Influenza, also known as the flu, is a communicable respiratory ailment initiated by influenza viruses. It is primarily treated by pharyngitis treatment which aids in relieving flu symptoms, like inflammation or irritation, and focuses on easing allergies and averting complications such as pneumonia and bronchitis. For instance, according to the European Centre for Disease Prevention and Control (ECDC), a government agency based in Sweden, during the 2022/2023 influenza season in the EU/EEA, the rate of positive influenza specimens touched 42% in the 51st week of 2022. The positivity rate then hovered around 28% from the 5th week to the 12th week of 2023. This increasing incidence, hence, is fueling the growth of the pharyngitis treatment market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12937&type=smp

#How Does the ProjectedPharyngitis Treatment Market Growth Compare Over the Forecast Period?

In recent times, the market size for pharyngitis treatment has experienced consistent growth. It is predicted to amplify from $2.27 billion in 2024 to $2.37 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%. The surge during the historic phase can be traced back to an increased occurrence and rising cases of the flu, an increased incidence of pharyngitis, enhanced awareness about pharyngitis, expanded access to healthcare facilities, and growing disposable incomes.

Anticipations are high for robust growth in the pharyngitis treatment market size in the forthcoming years. The market is expected to evolve to a size of $2.99 billion in 2029, with a compound annual growth rate (CAGR) of 6.0%. The anticipated growth during the projection period can be credited to the uptake of rapid point-of-care tests, the growing need for personalized medicine, the prevalence of antibiotic resistance, and the rising significance of hand hygiene. Key trends projected for this period consist of progress in research and development of pharyngitis treatments, integration of digital health technologies, and the rise of telehealth.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12937

What Are the Key Market Innovations in thePharyngitis Treatment Market Over the Coming Years?

Leading corporations in the pharyngitis treatment market are striving to develop ground-breaking products like oral monotherapy. This approach aims to boost patient compliance and offer effective and accessible treatment methods. Oral monotherapy means using a single oral medication to address a specific illness or disease. This treatment only uses one healing agent rather than mixed treatments to achieve the desired healing outcome. For example, in December 2023, the US FDA authorized the use of Fabhalta (iptacopan) by Novartis AG, a pharmaceutical entity based in Switzerland, marking it as the inaugural oral monotherapy for adults suffering from paroxysmal nocturnal hemoglobinuria (PNH). Obtained on [date], this progress symbolizes a substantial improvement by introducing a fresh treatment option that raises hemoglobin levels, thereby, eliminating the requirement for blood transfusions.

Who Are the Top Companies Driving Innovation and Growth in thePharyngitis Treatment Market?

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

Which Key Market Segments Comprise the Pharyngitis Treatment Market and Drive Its Revenue Growth?

The pharyngitis treatment market covered in this report is segmented –

1) By Drug Class: Beta Lactams, Macrolides, Cephalosporins, Fluoroquinolones, Tetracycline, Other Drug Classes

2) By Source of Infection: Viral, Bacterial

3) By Modes Of Delivery: Oral, Intravenous, Intramuscular, Other Modes Of Delivery

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Beta Lactams: Penicillins, Amoxicillin, Ampicillin

2) By Macrolides: Erythromycin, Azithromycin, Clarithromycin

3) By Cephalosporins: Cefuroxime, Ceftriaxone, Cefdinir

4) By Fluoroquinolones: Ciprofloxacin, Levofloxacin, Moxifloxacin

5) By Tetracycline: Doxycycline, Minocycline, Tetracycline

6) By Other Drug Classes: Clindamycin, Sulfonamides, Carbapenems

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12937&type=smp

Which Regions Are Emerging as Leaders in the Pharyngitis Treatment Market?

North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Pharyngitis Treatment Market 2025, By The Business Research Company:

Non-Steroidal Anti-inflammatory Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Leukemia Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Pharyngitis Treatment Market?

The expected increase in strep throat transmission is predicted to foster the expansion of the pharyngitis treatment market. Strep throat, a communicable bacterial infection, has its primary effect on the throat and tonsils. Swift and efficient treatment of this condition with antibiotics can relieve symptoms, thwart complications, and decrease the risk of infection transmission. For example, in June 2022, as per the US-based government agency – the Centers for Disease Control and Prevention, roughly 14,000 to 25,000 cases of invasive group A strep disease are diagnosed in the United States every year. In addition, strep diseases result in 5.2 million outpatient visits and 2.8 million antibiotic prescriptions every year. The escalating transmission of strep throat, therefore, influences the pharyngitis treatment market. An uptick in influenza cases is anticipated to spur the growth of the pharyngitis treatment market in the future. Influenza, also known as the flu, is a communicable respiratory ailment initiated by influenza viruses. It is primarily treated by pharyngitis treatment which aids in relieving flu symptoms, like inflammation or irritation, and focuses on easing allergies and averting complications such as pneumonia and bronchitis. For instance, according to the European Centre for Disease Prevention and Control (ECDC), a government agency based in Sweden, during the 2022/2023 influenza season in the EU/EEA, the rate of positive influenza specimens touched 42% in the 51st week of 2022. The positivity rate then hovered around 28% from the 5th week to the 12th week of 2023. This increasing incidence, hence, is fueling the growth of the pharyngitis treatment market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12937&type=smp

#How Does the ProjectedPharyngitis Treatment Market Growth Compare Over the Forecast Period?

In recent times, the market size for pharyngitis treatment has experienced consistent growth. It is predicted to amplify from $2.27 billion in 2024 to $2.37 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%. The surge during the historic phase can be traced back to an increased occurrence and rising cases of the flu, an increased incidence of pharyngitis, enhanced awareness about pharyngitis, expanded access to healthcare facilities, and growing disposable incomes.

Anticipations are high for robust growth in the pharyngitis treatment market size in the forthcoming years. The market is expected to evolve to a size of $2.99 billion in 2029, with a compound annual growth rate (CAGR) of 6.0%. The anticipated growth during the projection period can be credited to the uptake of rapid point-of-care tests, the growing need for personalized medicine, the prevalence of antibiotic resistance, and the rising significance of hand hygiene. Key trends projected for this period consist of progress in research and development of pharyngitis treatments, integration of digital health technologies, and the rise of telehealth.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12937

What Are the Key Market Innovations in thePharyngitis Treatment Market Over the Coming Years?

Leading corporations in the pharyngitis treatment market are striving to develop ground-breaking products like oral monotherapy. This approach aims to boost patient compliance and offer effective and accessible treatment methods. Oral monotherapy means using a single oral medication to address a specific illness or disease. This treatment only uses one healing agent rather than mixed treatments to achieve the desired healing outcome. For example, in December 2023, the US FDA authorized the use of Fabhalta (iptacopan) by Novartis AG, a pharmaceutical entity based in Switzerland, marking it as the inaugural oral monotherapy for adults suffering from paroxysmal nocturnal hemoglobinuria (PNH). Obtained on [date], this progress symbolizes a substantial improvement by introducing a fresh treatment option that raises hemoglobin levels, thereby, eliminating the requirement for blood transfusions.

Who Are the Top Companies Driving Innovation and Growth in thePharyngitis Treatment Market?

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

Which Key Market Segments Comprise the Pharyngitis Treatment Market and Drive Its Revenue Growth?

The pharyngitis treatment market covered in this report is segmented –

1) By Drug Class: Beta Lactams, Macrolides, Cephalosporins, Fluoroquinolones, Tetracycline, Other Drug Classes

2) By Source of Infection: Viral, Bacterial

3) By Modes Of Delivery: Oral, Intravenous, Intramuscular, Other Modes Of Delivery

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Beta Lactams: Penicillins, Amoxicillin, Ampicillin

2) By Macrolides: Erythromycin, Azithromycin, Clarithromycin

3) By Cephalosporins: Cefuroxime, Ceftriaxone, Cefdinir

4) By Fluoroquinolones: Ciprofloxacin, Levofloxacin, Moxifloxacin

5) By Tetracycline: Doxycycline, Minocycline, Tetracycline

6) By Other Drug Classes: Clindamycin, Sulfonamides, Carbapenems

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12937&type=smp

Which Regions Are Emerging as Leaders in the Pharyngitis Treatment Market?

North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Pharyngitis Treatment Market 2025, By The Business Research Company:

Non-Steroidal Anti-inflammatory Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Leukemia Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the pharyngitis treatment market right now?

The pharyngitis treatment market has expanded steadily, increasing from $2.27 billion in 2024 to $2.37 billion in 2025, with a CAGR of 4.5%. Growth has been driven by the high prevalence of flu, rising pharyngitis cases, increased awareness, better access to healthcare, and higher disposable incomes.

How fast Is the pharyngitis treatment market expected to grow, and what’s its future value?

The pharyngitis treatment market is anticipated to expand, reaching $2.99 billion in 2029 with a CAGR of 6.0%. Growth factors include the increasing adoption of rapid point-of-care tests, demand for personalized medicine, antibiotic resistance concerns, and a heightened focus on hand hygiene. Emerging trends include advancements in pharyngitis therapy research, digital health integration, and telehealth expansion.

Get your pharyngitis treatment market report here!

https://www.thebusinessresearchcompany.com/report/pharyngitis-treatment-global-market-report

What are the leading drivers of growth in the pharyngitis treatment market?

A surge in strep throat cases is poised to drive the growth of the pharyngitis treatment market. Strep throat is an infectious bacterial ailment predominantly affecting the throat and tonsils. Swift and effective treatment of strep throat using antibiotics can reduce symptoms, stave off complications, and lower the risk of transferring the infection to others. Data from the Centers for Disease Control and Prevention in June 2022 indicated that an estimated 14,000 to 25,000 invasive group A strep disease cases occur in the United States annually. Strep illnesses also account for approximately 5.2 million outpatient visits and 2.8 million annual antibiotic prescriptions. Consequently, strep throat’s escalating transmission bolsters the pharyngitis treatment market. The pharyngitis treatment market is also expected to be driven by an increase in influenza cases. Influenza, or the flu, is an infectious respiratory disease caused by influenza viruses. Pharyngitis treatment, typically used to manage influenza, mitigates the symptoms, which include inflammation or irritation, and prevents complications like pneumonia and bronchitis. For example, the European Centre for Disease Prevention and Control (ECDC) reported in July 2023 that 42% of influenza specimens tested positive in the 51st week of 2022 during the 2022/2023 flu season in the EU/EEA. Positivity hovered around 28% from the 5th to the 12th week of 2023. Therefore, the increasing prevalence of influenza is fuelling the expansion of the pharyngitis treatment market.

What are the key segments defining the pharyngitis treatment market?

The pharyngitis treatment market covered in this report is segmented –

1) By Drug Class: Beta Lactams, Macrolides, Cephalosporins, Fluoroquinolones, Tetracycline, Other Drug Classes

2) By Source of Infection: Viral, Bacterial

3) By Modes Of Delivery: Oral, Intravenous, Intramuscular, Other Modes Of Delivery

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Beta Lactams: Penicillins, Amoxicillin, Ampicillin

2) By Macrolides: Erythromycin, Azithromycin, Clarithromycin

3) By Cephalosporins: Cefuroxime, Ceftriaxone, Cefdinir

4) By Fluoroquinolones: Ciprofloxacin, Levofloxacin, Moxifloxacin

5) By Tetracycline: Doxycycline, Minocycline, Tetracycline

6) By Other Drug Classes: Clindamycin, Sulfonamides, Carbapenems

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12937&type=smp

Who are the key players steering the development of the pharyngitis treatment market?

Major companies operating in the pharyngitis treatment market are Pfizer Inc., GlaxoSmithKline PLC, Genentech Inc., Pliva Hrvatska D.o.o., Viatris Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Pliva Hrvatska D.o.o., LivaNova PLC, Genentech Inc.

What emerging trends are influencing the growth of the pharyngitis treatment market?

Leading firms in the pharyngitis treatment market are turning their focus towards creating advanced products like oral monotherapy, intending to improve patient compliance and deliver efficient, handy treatment alternatives. Oral monotherapy denotes the utilization of an individual medicine taken orally to mitigate a particular disorder or disease. This therapeutic approach implies administration of a single therapeutic agent instead of multiple combined treatments to achieve the therapy’s anticipated outcome. For example, in December 2023, The FDA granted approval to Novartis AG, a pharmaceutical corporation from Switzerland, for Fabhalta (iptacopan), marking it as the inaugural oral monotherapy for adult patients suffering from paroxysmal nocturnal hemoglobinuria (PNH). This achievement on [date] signifies a notable evolution by furnishing a novel treatment substitute that boosts hemoglobin levels, thereby abrogating the requirement for blood transfusions.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12937

Which regions are most influential in expanding the pharyngitis treatment market?

North America was the largest region in the pharyngitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharyngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Non-Steroidal Anti-inflammatory Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/non-steroidal-anti-inflammatory-drugs-global-market-report

Leukemia Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Digital Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: